Intrinsic Edge Capital Management’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
PCM
WA
Intrinsic Edge Capital Management's CSTL Position: Q1 2025 in Review
Intrinsic Edge Capital Management sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 232,711 shares — an estimated $6.2M sold.
Intrinsic Edge Capital Management first reported a position in CSTL in Q1 2021 and held it in 15 quarters. The position peaked at $12.5M in Q2 2021. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.
- Intrinsic Edge Capital Management reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
- Intrinsic Edge Capital Management sold 232,711 Castle Biosciences shares in Q1 2025, an estimated $6.2M.
- Intrinsic Edge Capital Management first reported a position in Castle Biosciences in Q1 2021 and held it in 15 quarters.
- Intrinsic Edge Capital Management's Castle Biosciences position peaked at $12.5M in Q2 2021.
- 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.
Based on Intrinsic Edge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.